CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the...

Related Keywords

China , South Korea , Suzhou , Jiangsu , Australia , United States , American , Republic Of Korea , , American Society Of Clinical Oncology , Cstone Pharmaceuticals , Ligachem Biosciences Inc , American Society , Clinical Oncology , Central Daylight Time , Ligachem Biosciences , South Korea Based ,